Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Revance Therapeutics Q4 EPS $(0.62) Beats $(0.72) Estimate, Sales $69.80M Beat $62.63M Estimate

Author: Happy Mohamed | February 28, 2024 05:26pm
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 65.93 percent increase over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $69.80 million which beat the analyst consensus estimate of $62.63 million by 11.45 percent. This is a 39.82 percent increase over sales of $49.92 million the same period last year.

Posted In: RVNC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist